TITLE

Forcing Pharma's Hand

AUTHOR(S)
Varmazis, Catherine
PUB. DATE
July 2007
SOURCE
Bio-IT World;Jul/Aug2007, Vol. 6 Issue 6, p38
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the issues concerning the policies issued by the International Committee of Medical Journal Editors (ICMJE). The policies were issued following criticisms on the hesitance of pharmaceutical companies to register ongoing clinical trials. According to ICMJE, the update on its policies will also include the registration of preliminary trials. The committee will not accept abstracts of less than 50 words.
ACCESSION #
26215658

 

Related Articles

  • “Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies”.  // AIDS Treatment News;6/24/2005, Issue 413, p6 

    Reprints the article "Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies," by R. Smith, which appeared in the May 2005 issue of "PLoS Medicine." Role of a clinical trial published in the journal as a way of promoting a new drug; Rarity of published articles on...

  • Likely country of origin in publications on randomised controlled trials and controlled clinical trials during the last 60 years. Gluud, Christian; Nikolova, Dimitrinka // Trials;2007, Vol. 8, p7 

    Background: The number of publications on clinical trials is unknown as well as the countries publishing most trial reports. To try to examine these questions we performed an ecological study. Methods: We searched the 454,449 records on publications in The Cochrane Central Register of Controlled...

  • Biomedical Industrial Sponsorship and Its Impact on the Medical Literature. Morris, Peter J. // World Journal of Surgery;Aug2006, Vol. 30 Issue 8, p1371 

    The article focuses on the issue of the influence of biomedical industrial sponsorship on medical literature. In order to bring a new drug onto the market clinical trials are conducted. These trials take place in clinics in both university and nonuniversity institutions and, for the most part,...

  • Drug giants fail to name compounds in trial database. Wadman, Meredith // Nature;6/2/2005, Vol. 435 Issue 7042, p548 

    The article reports that an international group of medical editors is challenging several leading pharmaceutical companies, saying that their reporting of clinical trials is deliberately incomplete. They argue that leading pharmaceutical companies are obeying the letter but not the spirit of a...

  • Quality of claims, references and the presentation of risk results in medical journal advertising: a comparative study in Australia, Malaysia and the United States. Othman, Noordin; Vitry, Agnes I.; Roughead, Elizabeth E. // BMC Public Health;2010, Vol. 10 Issue 1, p294 

    Background: Journal advertising is used by pharmaceutical companies to disseminate medicine information to doctors. The quality of claims, references and the presentation of risk results in Australia and the US has been questioned in several studies. No recent evidence is available on the...

  • The tribulations of community-based trials.  // CMAJ: Canadian Medical Association Journal;1/6/2004, Vol. 170 Issue 1, p33 

    Focuses on the trend of clinical trials sponsored by the pharmaceutical industry in Canada migrating from academic settings into the community. Challenges posed to physicians and the medical profession; Impact on issues of conflict of interest, patient safety and public interest; Percentage of...

  • Working the Pharmaceutical PIPELINE Databases. Breton, Tara // Searcher;Sep2003, Vol. 11 Issue 8, p32 

    Presents information on how to use a pharmaceutical pipeline database. Definition of a pipeline; Levels of a pharmaceutical pipeline; Information on the actual pipeline process.

  • Optimizing Phase III Trials. McLennan, Derek; Foley, Patrick // European Pharmaceutical Executive;Feb/Mar2007, p40 

    The article discusses some of the pitfalls inherent in the Phase III planning process and proposes some solutions for getting it right. The authors suggests that developing successful Phase III clinical trial strategies in today's European pharmaceutical marketing environment requires a balance...

  • Research trials: Registration, reporting and publication. Salvi, Vinita S. // Journal of Postgraduate Medicine;Apr-Jun2005, Vol. 51 Issue 2, p83 

    Discusses factors that prevent the making of research knowledge from clinical trials public. Absence of compulsion to register trials or their results in the public domain; Tendency of researchers not to publish trials that have either insignificant or negative findings. Publication bias with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics